Lundbeck says stroke drug Desmoteplase not better than placebo in phase 3 study |
|
|
|
Published
:
Fri, 01 Jun 2007 07:51 |
COPENHAGEN (Thomson Financial) - Danish pharmaceutical company Lundbeck AS said a phase 3 clinical study has shown no statistically significant difference in clinical outcome between patients treated with its stroke drug Desmoteplase and with placebo.The findings will not influence the group's financial result for 2007, Lundbeck added.The study was carried out by Lundbeck's partner PAION AG and Forest Laboratories Inc.gustav.sandstrom@thomson.comgs/jfrCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2367.09 |
-1.37 (
-0.06 %)
|
| SYMBOL (
2010-03-12 ) |
| LAST |
CHANGE
|
|
LONMIN
(
11:35am )
|
|
1998.00 |
+30.00 (
1.53 %)
|
| SYMBOL (
2010-03-12 )
|
| LAST |
CHANGE
|
| SYMBOL (
2010-03-12 )
|
| LAST |
CHANGE
|
|
| Portfolio
Manager |
|
|
|